

UPDATED COMMITMENTS

ResApp Health Limited (formerly Narhex Life Sciences Limited) (“**Company**”) confirms that the Public Offer under its Replacement Prospectus dated 26 May 2015 closed raising the maximum subscription amount of \$4,000,000. The Company intends to apply the funds raised from the Public Offer as follows:

Use of Funds	Amount (\$)
Expenses of the Offer	\$390,000
Product development	\$743,500
Clinical trials and R&D	\$1,500,000
Sales and marketing	\$100,000
Corporate and administration	\$989,000
Working capital	\$277,500
TOTAL	\$4,000,000

Note: Corporate and Administration expenses include management and board fees, accounting and legal fees, ASIC and ASX fees, insurance, rent and other expenses.